GLUE Sold Off on GFORCE-1 Because the Bar Had Already Moved
Biomarkers improved, but Phase 1 data, rivals, and the ZEUS miss kept buyers on the sidelines.
Biomarkers improved, but Phase 1 data, rivals, and the ZEUS miss kept buyers on the sidelines.
Wainwright cites a $565M enterprise value, cash into 2029, and multiple trials.
Monte Rosa Therapeutics (GLUE) announces positive Phase 1 results for MRT-8102, showing 85% reduction in inflammation markers and potential for preventing cardiovascular disease.
Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.